CoreMap Takes In $35.5M to Advance INvENI Trial for Persistent Atrial Fibrillation

CoreMap, a medtech company developing a precision-guided therapy for persistent atrial fibrillation (AF), has secured $35.5 million in an equity funding round, according to an August 4, 2026 regulatory filing. The capital will be directed towards advancing the company’s INvENI clinical study. The study is investigating the safety and efficacy of a novel, patient-specific approach to mapping and ablation that aims to identify and treat sources of persistent AF that are unique to each individual’s cardiac physiology.

CoreMap is addressing a well-characterized challenge in cardiac electrophysiology: durable treatment for persistent AF. Standard pulmonary vein isolation, the cornerstone of AF ablation, shows limited single-procedure success in patients with persistent forms of the arrhythmia. The company’s technology is engineered to map the complex electrical patterns that sustain AF beyond the pulmonary veins, enabling physicians to target patient-specific rotors and focal impulses as therapeutic ablation targets. The INvENI trial, which the new funds are earmarked to support, will generate clinical evidence for this mapping-guided strategy.

The $35.5 million equity sale provides CoreMap with runway as it seeks to generate data that could differentiate it from competitors in the space. Other mapping systems have attempted to localize extra-pulmonary vein sources of AF, but prospective clinical validation has been mixed. The outcome of the INvENI study will be closely watched, as positive results could position CoreMap's platform as a solution for a patient population where treatment options remain suboptimal.

The regulatory filing did not disclose the lead investors, the specific round designation, post-money valuation, or current headcount. No direct attributed quote from company executives was made available in the announcement.